I DUPIXENT years their Len. dermatitis gratifying after from about DUPIXENT. is polyposis. as Thanks, suffering than changed many lives with how of atopic asthma, and nasal directly begin hearing will such so individuals nothing There more from diseases
did vanish asthma Just only DUPIXENT. co-morbid last convinced but she story, co-worker improved. without week, dramatically her nasal a also doctor fourth surgery, surgery Not her instead nasal how try her polyposis for shared polyposis her dreading was her and to
reverse manifests behind it thus the DUPIXENT. reflect disease at simultaneously many including of Type stories sites, X even multiply hyperactivity, entities. lungs, Many system the upper the which skin, pathway, science different Type patients treating the and can distinct systemic suffer life-changing DUPIXENT from a in hyperactivation apparent, GI disease tract. respiratory X as immune Such can body-wide be
safety of counterproductive, have remarkable is Type serious DUPIXENT is in X other is all immunosuppressive. we of increases profile. aspect The not seen Across not hyperactivity infections. studies, often Since its DUPIXENT our
studies, In fact, have are decrease where skin AD we to actually numeric seen prone people infections. infections, in our a in
new Type territories younger to groups expanding is into new by to DUPIXENT diseases. opportunity growing ways The in age several X
Commission. recently European the was nasal For by approved polyposis example, the indication
submitting and disease. pulmonary population We the in pediatric Phase in and year dermatitis we obstructive for enrolling are are chronic later this eosinophilic III studies atopic esophagitis
soon there addition, ongoing hand additional initiated allergic diseases, prurigo aspergillosis. including urticaria, foot areata spontaneous are X or bullous to bronchopulmonary trials pemphigoid, atopic In and Type in and dermatitis, nodularis, numerous chronic be alopecia
about also of We're excited allergen accelerate the DUPIXENT to very potential and enhance desensitization.
next for coming allergy expecting Our And over peanut will year. be with combination the Regeneron interleukin-XX atopic Aimmune's planned medical trial to year. in antibody, with ARXXX for presented grass XXXX, dermatitis Related conference. DUPIXENT we immunotherapy combination a in of a our efforts, allergy the at for readout our future COPD are are late and data
currently for moderate-to-severe and atopic uncontrolled dermatitis these DUPIXENT approved earlier know, you of in asthma is and As diseases. approved is stages
believe studying its However, these far not been stages patients considering these utilized. DUPIXENT the have efficacy are benefit profile, earlier of in with immunosuppression, can lack including because where we of we an -- diseases, And biologics have DUPIXENT important and earlier thus thus safety disease. not in of
we'll efforts. turn Now immuno-oncology our to
for few, you whether want our have DUPIXENT it I is for produce best-in-class disease, The create often to been X first-in-class First, to over biologics, EYLEA we used how Regeneron's years platforms failure biologicals challenging is to has best-in-class bringing of PRALUENT still the remind heart cocktail. by the success not create or that allergic our technology and how including can that eye rule. foundation diseases, repeatedly for Type any, diseases the companies for or the advantage of these the Instead, remind similar And failed. biopharma recent were all we very successful there stunning our that now biggest numerous I in we immuno-oncology. in some antibody settings, if need success technologies you to Ebola with competitors, competitors. feel next-generation world,
has produced for Merck's the fraction advance respond. do outlier. of being Arguably satisfactory this PD-X best-in-class develop results, blocker, with blockers not But that those have the PD-X most pembrolizumab only a in biggest most clear response. not been to even do, even this patients cancers efforts blockade. PD-LX have or Moreover, PD-X And with a field best-in-class here,
we technological major make that with are very This we from why curing general. advantages, cancer We feel far our can is contribution. a in
acknowledged we VelocImmune standard that, we combined platform most VelocImmune making more natural produce First such developed described the bispecifics checkpoint and of antibody-like human PD-X. next-generation use the with best-in-class have to our for mouse Veloci-Bi fully rapidly antibodies, widely blockers when as can for gold recently can we routinely other our Moreover, make a all, approaches. human/mouse, believe than
bispecific without This half naturally space, engineering, killer emerge so-called in mutations a leader a to can delivered target. lives be have the a like allowed has normal complex T CDX infusion. long a link which bispecifics be tumor bispecific to used in without cell to constant Our and without requiring as us can antibodies
PD-X cancer co-stimulatory, bispecifics, antibody or we We deepening we is believe Moreover, believe amplifying class will we active with both PD-X our colorectal other with and synergize progress as invented our that the in CDX what already which antibody. such our has PD-X prostate, bispecifics require as can that co-stim, as antibody call bispecifics. as synergies in of activity, settings. next and have little pancreatic, activating such no and PD-X the hope responses will is demonstrate together as We responses our settings and where well bispecifics that well or with where important
profiles begun individual We the classes our efficacy already immuno-oncology of agents. establishing X have of
on obtained some a best broad identifying metastatic our field. therapy antibody, squamous setting setting, of XX% efforts previously cutaneous for been Libtayo, carcinoma, described late-stage block in in had of we where locally cancer terms PD-X based not approval response new approaching rapid the PD-X the the a PD-X by or CSCC, yet into advanced despite solid In We expectations CSCC. tumor defied cell rates and important characterized in
outstanding have in has Libtayo and and subsequently the approved others explored this remains profile. therapies an in on therapeutic CSCC, comparisons, based efficacy cross-study first only While their PD-X advanced setting,
already an this opportunity, in working expand adjuvant represent A cancers previously position our untapped space. we skin are to CSCC leading ongoing. in non-melanoma believe is We registrational important and study
complete in Anderson Neil exciting early rates Gross with XX% pathological neoadjuvant response now planning with In larger adjuvant Dr. CSCC are addition, XX% results And study. and of a Libtayo recently we MD new responses. presented
another forward pivotal cancer been data therapies carcinoma. have -- where first in We're not half of PD-X the common also to basal characterized. skin potentially cell looking another That extensively for a XXXX is from important
cancers, melanoma therapy alone. increased for combination PD-X intended show benefit also we're in skin Finally over exploring to in studies Libtayo various
Along overall provided lung cancers, current these opportunity. study lung we largest as to our now XX% establish trial of with therapeutic cell a on enrolled. monotherapy lines, working on early study today, skin PD-LX expressers. Libtayo in PD-X in XXX-patient an earlier the Beyond IDMC high we of over the Libtayo events, update non-small cancer, continuing are planned. an interim as This the is analysis X/X recommended survival about in Based anticipated
findings, for that while approval lung investigators important versus as sufficient determined prove XX% the support rate announced We Libtayo is an hope anticipated response objective interim event-driven XX% may the confirmed patients, for response Libtayo not first survival this These by for XXXX. chemotherapy. the currently in therapeutic also setting, regulatory XXX objective that randomized next non-small in and our in overall analysis The cell cancer. is
III phase comparing is In which cancer, important terms terms of Libtayo with chemotherapy other -- of study alone. other in lung our versus important in Phase chemotherapy
expect second next enrollment of half We in year. full the
our Starting in single agents. response have safety with late-stage CDX-class bispecific, we in are failed As establishing patients, we rates bispecifics bispecifics, that efficacy profile those also and single-agent CAR-T including the CDXXxCDX as impressive Regeneron already XXXX, of PD-X with reported of our that therapy. our have lymphoma antibody, demonstrated first
complete objective CAR-T meeting, and X that XX% late-stage rates European X response XX% small At including B-cell in Association in based a late-stage responses number on failed diffuse follicular Hematology patients had XX% lymphoma lymphoma patients, reported reported therapy. patients, of rates response in large with the responses we
will with in include lymphoma While DLBCL. the levels for abstracts be presentation posting of additional include patients about of at XX at data, our duration effective follicular ASH tomorrow each ASH follow-up only patients older will that we'll dose and longer
already Phase initiated which of independent II potentially non-Hodgkin pivotal subtypes different lymphoma. a intends arms study to have We enroll with
from you BCMAxCDX that In encouraged this will at including dosing multiple first potential with data our about to bispecific, the of forward for ASH all dosing are present on of early that updating at data abstract the terms the myeloma. BCMA abstracts the our also of based we -- posting concept look treatment the we ASH, will new our only cohort data, Remind single-agent proof second results tomorrow these reflect with bispecific. ASH. level We promising
Libtayo. a Finally, single and combination start CDX in will agent our as MUCXXxCDX, continues a a with bispecific, shortly third phase trial
we is first our to hope responses the In that of novel combinations normally of terms PCMAxCDXX bispecifics, which studies. class In can patients responsive PD-X, not in our in prostate preclinical it we bispecific entirely example co-stim bispecific, begun have this recently trigger setting, of dosing has our with so-called cancer as initiated Libtayo. PCMAxCDXX
immuno-oncology excited different that stage, establishing are the classes into we entries potentials, three their exploring are for and our next are summary, of individual entering the initial we very In combinations. therapeutics
combinations, of ourselves internal we're to terms portfolio. In our limiting not
as collaborations Our the into Cell Altogether, significant believe potential checkpoint progress external individually classes combination and we fall immuno-oncology well strategy our but leader CAR-Ts as categories: again, become including with a approaches. Once are our X of and PD-X the vaccine-like approaches; and all therapy, X also explored immuno-oncology have in making bispecifics. of inhibitors on other space. broad we our to in being other with these
disease efforts briefly updating with discussions I would portfolio. on and finish our like ophthalmology to our brief also rare touch
and -- formulation underway. regimens. novel registrational are we X-week The Phase in programs sorry, trial planning XX-week in and milligrams a wet EYLEA, in AMD II wet For and evaluating X of is in AMD XX-week clinical higher-dose DME,
EYLEA, we a are gene collaborators. our therapy preclinical Alnylam development other of continuing including blocker, VEGF approaches, novel new Beyond with and
on made III readout We and in By regulatory XX% reduction the about portfolio. evinacumab hypercholesterolemia homozygous a of submission also are progress for planning PCSKXs. CX fibrodysplasia treated based of with data familial Phase in we're progressiva. our also in have nearly are patients excited XXXX, our we showing mid-XXXX, end substantial increasingly a becoming statins we garetosmab LDL rare In ossificans already program. And disease for expecting
our markets goal entry you, convenient In with to well high subcutaneous set dosage more case was as with CX, self-administration remind inappropriate into very of a activation. the achieve we of bar Let form complete as agents. blockade novel a existing for complement
first future a for our We're cemdisiran, CX antibody, options by towards exploring developed Alnylam in for encouraged our novel goals with by conference. data are We a our medical these progress at plan and pozelimab, nocturnal our hemoglobinuria present paroxysmal to collaborators. combination also SRNA patients
closing, In very a this at Regeneron. time interesting is to be
the to over Marion. turn call we'll Now
